[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"comorbidities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:comorbidities":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,80,113,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100419979","access-to-kidney-transplant-of-obese-patients-beginning-dialysis-100419979",false,"NCT04748770","Access to Kidney Transplant of Obese Patients Beginning Dialysis","Transplantob","Inclusion Criteria:\n\n* Age over 18 years old.\n* Patients with BMI≥30 kg\u002Fm2 (for study population) and 25≤BMI≤30 kg\u002Fm2(for control population) one month after dialysis initiation.\n* Patients agree with their data collection.\n\nExclusion Criteria:\n\n* Patients with bariatric surgery history.\n* Patients needed dialysis for graft dysfunction.\n* Data loss.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Obesity is in constant increase all over the world and affects 35% of the global population according to the World Health Organisation. It is associated with other cardiovascular risk factors (particularly hypertension and diabetes) and with high morbi-mortality. It is also responsible for an increase of the risk of developing chronic kidney diseases (CKD). In fact, obese patients represent 25% of the dialysis population and Picardy is one of the most affected areas. However, their access to kidney transplant is still restricted and the reasons are not completely understood.",[24,25,26,27],"Kidney Transplant Access","Obese Patients","Dialysis","Comorbidities",[29,30,31,32],"Kidney transplant access","obese patients","dialysis","comorbidities","RECRUITING","2026-06-12",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2021-01-11",{"date":41,"type":20},"2026-06",{"name":43,"class":44},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":45},"100611830","phase-3-commodities-trial-initial-dual-oral-therapy-vs-monotherapy-in-pah-with-cardiovascular-comorbidities-100611830","NCT07245680","COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities","Comparison of Initial Dual Oral COMbination Therapy to MOnotherapy in Pulmonary Arterial Hypertension With Cardiovascular comorbiDITIES","COMMODITIES","Inclusion Criteria:\n\n* Initial PAH diagnosis \\\u003C 6 months preceding randomisation\n\n  * Negative vasoreactivity test\n  * Treatment-naïve PAH (group 1): idiopathic, heritable, associated with drugs and toxin, associated with connective tissue disease, HIV infection or systemic-to-pulmonary congenital shunt corrected for more than one year\n  * Meet all of the following hemodynamic criteria by means of a RHC prior to screening:\n* mPAP≥25 mmHg and\n* PAWP\\\u003C15 mmHg and\n* with PVR≥3 WU\n\n  • Presence of at least two of the following criteria, as listed in the European pulmonary hypertension guidelines:\n* History of essential hypertension\n* Diabetes mellitus (any type)\n* Obesity (defined by a BMI ≥30 kg\u002Fm2)\n* Coronary heart disease (established by any of the following: history of myocardial infarction, history of percutaneous coronary intervention, angiographic evidence of coronary artery disease (\\>50% stenosis in ≥1 vessel), positive ST, previous coronary artery bypass graft, stable angina)\n\n  * Participant able to understand the study procedures\n  * For women of childbearing potential (WOCBP), effective form of contraception\\* from screening up to 1 month following discontinuation of the last study treatment\n  * Affiliation to the french social security regime\n  * Signed written informed consent\n\nExclusion Criteria:\n\n* Porto-pulmonary hypertension\n* Uncorrected systemic-to-pulmonary congenital shunt\n* Evidence of thromboembolic disease assessed by ventilation perfusion (V\u002FQ) lung scan or CT pulmonary angiography\n* Patients listed for lung or heart-lung transplantation at time of screening\n* Patients on any PAH-specific drug therapy at any time preceding randomisation\n* Known moderate-to-severe restrictive lung disease (i.e., total lung capacity \\\u003C 60% of predicted value) or obstructive lung disease (i.e., forced expiratory volume in one second \\[FEV1\\] \\\u003C 60% of predicted, with FEV1 \u002F forced vital capacity \\\u003C 65%) or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema).\n* Known or suspected pulmonary veno-occlusive disease (PVOD)\n* Severe renal insufficiency (creatinine clearance \\\u003C 30 mL\u002Fmin)\n* Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin \\> 3 x ULN or serum AST and\u002For ALT \\> 3xULN (assessed by local laboratory at screening) and\u002For Child-Pugh Class C.\n* Haemoglobin \\\u003C 10 g\u002FdL\n* Patient under guardianship curatorship, deprived of liberty\n* Pregnant women, or breast-feeding women\n* Treatment with other PDE-5i for erectile dysfunction\n* Ongoing or planned treatment with nitrates and\u002For doxazosin.\n* Ongoing or planned treatment with riociguat\n* Treatment with strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤28 days preceding randomisation",{"count":55,"type":20},186,"INTERVENTIONAL",[58],"PHASE3","Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities. Current guidelines recommend initial combination therapy, but evidence is lacking for patients with significant comorbidities who are often excluded from clinical trials.\n\nThe COMMODITIES trial is a multicenter, randomized, controlled study designed to compare the efficacy and safety of initial dual oral combination therapy (tadalafil and ambrisentan) versus oral monotherapy in newly diagnosed PAH patients with at least two cardiovascular comorbidities. The study aims to provide robust evidence to guide treatment strategies in this high-risk population.",[61,27,62],"Pulmonary Arterial Hypertension (PAH)","Cardiovascular Disease (CVD)",[64,65,66,67,68,69,70],"PAH","Endothelin Receptor Antagonist (Ambrisentan)","Phosphodiesterase-5 Inhibitor (Tadalafil)","Cardiovascular Comorbidities","Combination Therapy","Randomized Controlled Trial","Pulmonary arterial hypertension","2026-05-12",{"date":73,"type":37},"2026-05-13",{"date":75,"type":37},"2026-04-28",{"date":77,"type":20},"2029-02-14",{"name":79,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":56,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":45},"100615203","tailored-stapled-sadi-s-initial-report-and-preliminary-results-100615203","NCT07289555","Tailored Stapled SADI-S: Initial Report and Preliminary Results","Tailored Stapled Single Anastomosis Duodeno-ileal Bypass With Sleeve Gastrectomy (SADI-S): Initial Report and Preliminary Results","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* BMI ≥35 kg\u002Fm² or BMI ≥30 kg\u002Fm² with obesity-related comorbidities such as type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease.\n* Willingness to adhere to follow-up visits and testing.\n* Indicated for revisional SADI-S post sleeve gastrectomy for inadequate weight loss or weight regain.\n\nExclusion Criteria:\n\n* Severe uncontrolled medical or psychiatric conditions preventing adherence to the protocol.\n* Known short bowel syndrome or previous extensive bowel resections or intraoperative finding of extensive bowel adhesions.","65 Years",{"count":89,"type":20},40,[91],"NA","Obesity is a serious health problem worldwide and can lead to many diseases such as diabetes, high blood pressure, heart disease, and sleep apnea. When lifestyle changes and medications are not enough, metabolic and bariatric surgery (MBS) is currently the most effective and long-lasting treatment option.\n\nThis study focuses on one of the newer types of bariatric surgery called Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S). This procedure combines two parts:\n\nSleeve gastrectomy, which reduces the size of the stomach so the patient feels full after eating a small amount.\n\nDuodeno-ileal bypass, which shortens the path food takes through the small intestine to reduce calorie absorption.\n\nOur hospital's surgical team is studying a tailored version of this operation, where the length of the bypassed intestine is adjusted to each patient's anatomy. We believe this personalized approach may improve weight loss results while lowering the risk of vitamin and nutrient deficiencies.\n\nThe study will include 40 adult patients with obesity who are undergoing SADI-S surgery, either as their first weight loss operation or as a revision surgery after an earlier sleeve gastrectomy. During the operation, surgeons will measure the total length of each patient's small intestine and use a formula to decide how much of it should be bypassed. The duodeno-ileal connection will be made using a stapled technique, which is expected to be safe and efficient.\n\nAfter surgery, patients will be followed regularly at 1, 3, 6, 9, and 12 months, and then once per year. At each visit, the study team will monitor weight loss, body mass index (BMI), resolution of diabetes and other obesity-related conditions, nutritional status (including vitamins and minerals), and any side effects such as diarrhea, reflux, or nutritional problems.\n\nThe goal of this study is to learn whether this tailored SADI-S technique can provide strong, sustained weight loss and health improvement with fewer long-term complications. The results will help improve surgical planning for future patients by showing whether measuring and customizing the bypass length is safer and more effective than using a fixed length.\n\nAll data collected will be kept confidential. Patients' participation in the study will not change their regular care or follow-up, and they can withdraw at any time without affecting their treatment.",[94,95,96,27],"Morbid Obesity","Bariatric Surgery","Malnutrition",[98,99,100,101,102],"SADI-S","Bariatric surgery","Limb length tailoring","Weight loss outcomes","Nutritional status","2025-12-04",{"date":105,"type":37},"2025-12-17",{"date":107,"type":37},"2024-06-01",{"date":109,"type":20},"2026-12-31",{"name":111,"class":112},"El-Sahel Teaching Hospital","OTHER_GOV",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":124,"studyType":21,"phases":4,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100613666","headache-registration-and-followup-initiated-by-tongji-hospital-hust-100613666","NCT07269561","Headache Registration and Followup Initiated by Tongji Hospital, HUST","HEALTH","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for headache classification according to the International Classification of Headache Disorders 3rd edition (ICHD-3, 2018) Age between 6-70 years Voluntary participation with consent Good compliance with follow-up and questionnaire surveys\n\nExclusion Criteria:\n\n* Complex headache etiology, e.g., presence of ≥3 distinct factors causing headache Presence of severe systemic diseases or life expectancy less than 10 years Significant cognitive or psychiatric issues that prevent completion of questionnaire follow-ups and clinical assessments","6 Years","70 Years",{"count":123,"type":20},50000,"10 Years","Headache is one of the most common chief complaints in clinical practice, with a high global prevalence rate. It may originate from a primary headache disorder or manifest as a clinical symptom of various diseases due to the complexity of its triggers, specific types, diagnosis, and treatment which present significant challenges. As people's life pace continues to accelerate and psychological and physiological pressures increase, many patients experience headache symptoms, leading to a growing number of patients seeking treatment in neurology departments. The increasing incidence of headache conditions has resulted in a decline in patients' quality of life.\n\nTherefore, this research is part of Hubei Province's major project \"Discovery and Functional Research of Major Disease Targets Based on Genetic Big Data.\" The study aims to establish a clinical cohort and develop a precise diagnosis and treatment system for headaches. This system will collect the history of headache sufferers, record the real-world treatment data, and incorporate sample banks, multi-dimensional databases, pre-clinical drug evaluation platforms, and clinical efficacy precise dynamic monitoring models through immunotherapy and other cutting-edge biotechnologies, multi-omics detection technologies, and big data bioinformatics analysis technologies.\n\nThe system will provide scientists and clinicians with auxiliary diagnostic and treatment decision support, offer reliable screening targets for early headache diagnosis and drug development companies, accelerate the latest headache diagnosis and targeted treatment, and achieve breakthrough advances in headache prevention and cure.",[127,27],"Headache",[127,129,130,131,132],"prediction models","database","cohort","Real world observation","2025-11-26",{"date":135,"type":37},"2025-12-08",{"date":137,"type":37},"2024-01-01",{"date":139,"type":20},"2028-12-31",{"name":141,"class":44},"Tongji Hospital",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":164,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":45},"100605647","association-of-pocd-with-circulating-biomarkers-in-patients-undergoing-tur-of-bladder-tumor-100605647","NCT07165236","Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor","Association of Perioperative Cognitive Dysfunction With Circulating Biomarkers of Neurological Damage in Patients Underging Transurethral Resection of Bladder Tumor","Inclusion Criteria:\n\n* adult patients from 18-80 years,\n* elective operations of tumor bladder cancer (TUR),\n* patients can communicate,\n* patients who can sign the information consent and questionnaires\n\nExclusion Criteria:\n\n* patients under the age of 18,\n* patients above 80 years,\n* patients who are unable to communicate\n* patients who do not understand informed consent for the research,\n* patients who are unable to write\n* emergency surgery,\n* patients with proven hypersensitivity to some of the drugs used in the study\n* patients in a state of shock, septic, or hemorrhagic patients with neurodevelopmental disorders","80 Years",{"count":151,"type":20},42,"Bladder tumor is one of the most widespread tumors in the world, with increasing prevalence at the global level. One of the procedures in patients with bladder tumors is transurethral resection of the bladder (TURM) most often performed endoscopically under general anesthesia. This patient population has certain characteristics in common. One of them is exposure to common risk factors for the formation of bladder tumors, such as aniline dyes and solvents. These substances are associated with the onset of neurodegeneration and oxidative stress. Smoking is another factor that affects the formation of bladder tumor. A significant part of patients with bladder tumor are an elderly population, which is repeatedly exposed to surgical procedures, with numerous comorbidities, with a high risk of postoperative complications and the development of perioperative cognitive deficits, which can further complicate the postoperative course and further treatment. In the group of patients with a bladder tumor who will undergo TURM, no evaluation of risk factors related to perioperative cognitive deficit was performed, nor was there an examination of the perioperative cognitive deficit itself. In them, the identification of factors for postoperative cognitive disorder is essential. The concept of clinical frailty is becoming more important and relevant when providing healthcare services to patients. The use of the clinical frailty scale as a tool in clinical practice provides information on the adequate direction of care for patients. Decrease in muscle strength can lead to limitations in the functioning of a certain individuals. In recent years muscle strength has come to be a very important component of health, regardless of a person's age and clinical condition.The hand grip test is a test used to measure the maximum isometric strength of the hand and forearm muscles. The MMSE test and MoCA are the most frequently used methods in the detection of cognitive impairment in clinical and research fields. In addition to laboratory indicators of organic function, circulating indicators of neuroinflammation, like S100B and neuron-specific enolase, will be correlated with the patient's cognitive status.So far, no research has been conducted on the dynamics of indicators of organic function, circulating indicators of neuroinflammation, perioperative cognitive changes and clinical fraility in patients undergoing bladder tumor operation.",[154,155,156,157,158,159,160,27,161,162,163],"Cognitive Decline","Urinary Bladder Cancer","Frail","Biomarker","General Anesthesia","Hand Grip Strength","Cognitive Testing","Demographic Data","Socio-economic Status","Perioperative Complications",[165,166,167,168,169,170],"general anesthesia","postoperative cognitive complications","urinary bladder neoplasm","perioperative period","frail older adult","S100b","2025-09-02",{"date":173,"type":37},"2025-09-10",{"date":175,"type":37},"2024-11-28",{"date":177,"type":20},"2029-10-01",{"name":179,"class":44},"Osijek University Hospital"]